Literature DB >> 21768871

Sertraline-induced ventricular tachycardia.

Nishit H Patel1, Harsh Golwala, Stavros Stavrakis, Eliot Schechter.   

Abstract

Sertraline is a selective serotonin reuptake inhibitor, which is a commonly used drug for major depressive disorder. Most frequently reported adverse effects of sertraline in patients receiving 50-150 mg/d are dry mouth, headache, diarrhea, nausea, vomiting, sweating, and dizziness. We hereby report one of the few cases of sertraline-induced ventricular tachycardia, which has been for the first time objectively assessed by the Naranjo scale. We therefore urge the primary care physicians and the cardiologists to keep sertraline as a possible precipitating factor for evaluation of ventricular tachycardia.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 21768871     DOI: 10.1097/MJT.0b013e3182192d6e

Source DB:  PubMed          Journal:  Am J Ther        ISSN: 1075-2765            Impact factor:   2.688


  4 in total

1.  Evidence for cardiotoxicity associated with sertraline in rats.

Authors:  Sinem Ilgin; Volkan Kilic; Merve Baysal; Gozde Aydogan-Kilic; Seyda Ucarcan; Begum Dermenci; Ozlem Atli
Journal:  Toxicol Res (Camb)       Date:  2018-04-06       Impact factor: 3.524

2.  Reversible Complete Heart Block in a Pregnant Woman Related to Sertraline Treatment.

Authors:  Frederik Cosedis Enevoldsen; Jens Cosedis Nielsen; Torsten Bloch Rasmussen
Journal:  CJC Open       Date:  2021-09-29

3.  Wide spectrum of inhibitory effects of sertraline on cardiac ion channels.

Authors:  Hyang-Ae Lee; Ki-Suk Kim; Sung-Ae Hyun; Sung-Gurl Park; Sung Joon Kim
Journal:  Korean J Physiol Pharmacol       Date:  2012-10-18       Impact factor: 2.016

4.  Risk of Ventricular Arrhythmia with Citalopram and Escitalopram: A Population-Based Study.

Authors:  Elena Qirjazi; Eric McArthur; Danielle M Nash; Stephanie N Dixon; Matthew A Weir; Akshya Vasudev; Racquel Jandoc; Lorne J Gula; Matthew J Oliver; Ron Wald; Amit X Garg
Journal:  PLoS One       Date:  2016-08-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.